Registration Dossier

Administrative data

acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference Type:
study report
Report Date:

Materials and methods

Test guideline
according to
OECD Guideline 402 (Acute Dermal Toxicity)
Principles of method if other than guideline:
Resorcinol diacetate was administered to five Wistar rats of each sex by a single dermal application at 2000 mg/kg body weight for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (Day 15).
GLP compliance:
Test type:
other: singel application of 2000 mg/kg bw.
Limit test:

Test material

Specific details on test material used for the study:
Identification: Resorcinol diacetate
Appearance: Brown liquid
Purity/Composition: 98.52% (GC)
Test item storage: At room temperature
CAS Number: 108-58-7
Molecular formula: C10H10O4
Molecular weight: 194.18
pH (1% in water,
indicative range): 3.60 – 3.51 (determined by Charles River Den Bosch)
Specific gravity/density: 1.18

Test animals

Details on test animals and environmental conditions:
Test System
Species: Rat, Wistar strain, Crl:WI (Han) (outbred, SPF-Quality). Recognized by international guidelines as the recommended test system (e.g. OECD, EC).
Source: Charles River Deutschland, Sulzfeld, Germany.
Number of animals: 5 males and 5 females (females were nulliparous and nonpregnant).
Age and body weight: Young adult animals (approx. 10-11 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex mean. Identification Tail mark with indelible ink.
Health inspection: At least prior to dosing. It was ensured that the animals were healthy and that the skin to be treated was intact and free from any abnormality.

Animal Husbandry
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 air changes/hour, and a 12-hour light/12-hour dark cycle. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Individually housed in labeled Makrolon cages (MIII type, height 18 cm.) containing sterilized sawdust as bedding material and paper as cage-enrichment.
Acclimatization period was at least 5 days before start of treatment under laboratory conditions. During the acclimatization period the animals were group housed in Makrolon cages (MIV type, height 18 cm).
Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Free access to tap water.

Diet, water, bedding and cage enrichment evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study.

Administration / exposure

Type of coverage:
unchanged (no vehicle)
Details on dermal exposure:
Method: Dermal application.
Clipping: One day before exposure (Day -1) an area of approximately 5x7 cm on the back of each animal was clipped.
Application: The test item was applied on an area of approx. 10% of the total body surface, i.e. approx. 25 cm² for males and 18 cm² for females. The test item was held in contact with the skin with a dressing, consisting of a surgical gauze patch, successively covered with aluminum foil and Coban elastic bandage*. A piece of Micropore tape* was additionally used for fixation of the bandages in females only.
Frequency: Single dosage, on Day 1.
Dose level (volume): 2000 mg/kg (1.69 mL/kg) body weight. Dose volume calculated as dose level (g/kg) / density (g/mL).
Duration of exposure:
Application period: 24 hours, after which dressings were removed and the skin cleaned of residual test item using tap water.
Dose level (volume): 2000 mg/kg (1.69 mL/kg) body weight.
No. of animals per sex per dose:
Five male and 5 female rats/dose
Control animals:
not required
Details on study design:
Mortality/Viability: Twice daily.
Body weights: Days 1 (pre-administration), 8 and 15.
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15. The time of onset, degree and duration were recorded and the symptoms graded according to fixed scales:
Maximum grade 4: grading slight (1) to very severe (4)
Maximum grade 3: grading slight (1) to severe (3)
Maximum grade 1: presence is scored (1).
Necropsy: At the end of the observation period, all animals were sacrificed by oxygen/carbon dioxide procedure and subjected to necropsy. Descriptions of all internal macroscopic abnormalities were recorded.
At the maximum applied dose (2000 mg/kg bw) no mortality occurred. Therefore a statistical evaluation is not necessary.

Results and discussion

Effect levels
Dose descriptor:
discriminating dose
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
No mortality occurred.
Clinical signs:
General erythema, scales, swelling and/or scabs were seen in the treated skin-area of the majority of animals during the observation period. Chromodacryorrhoea of the snout was noted for one female on Day 2. No further systemic clinical signs were noted.
Body weight:
The mean body weight gain during the observation period was within the range expected for rats used in this type of study.
Gross pathology:
No abnormalities were found at macroscopic post mortem examination of the animals.

Any other information on results incl. tables

The dermal LD50 value of Resorcinol diacetate in Wistar rats was established to exceed 2000 mg/kg body weight.

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
LD50 > 2000 mg/kg bw (discriminating dose). No mortality occurred.
Executive summary:

Resorcinol diacetate was administered to five Wistar rats of each sex by a single dermal application at 2000 mg/kg body weight for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (Day 15). LD50 > 2000 mg/kg bw (discriminating dose). No mortality occurred.